Global Sepsis Diagnostics Market to grow with a CAGR of 7.22%.
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Sepsis Diagnostics Market.
According to TechSci Research
report, “Global Sepsis Diagnostics Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global Sepsis Diagnostics Market has
valued at USD 571.03 million in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 7.22% through 2028. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
The increasing geriatric
population is a driver for the global sepsis diagnostics market. Elderly
individuals are more susceptible to infections due to age-related changes in
the immune system (immunosenescence) and the presence of underlying chronic
conditions. As a result, they are at a higher risk of developing sepsis. The
elderly population often has a higher prevalence of chronic diseases, such as
diabetes, cardiovascular disease, and respiratory conditions. These chronic
illnesses can increase the likelihood of infection and sepsis. Elderly
individuals are more likely to have multiple comorbidities, which can
complicate the diagnosis and management of sepsis. Accurate and timely
diagnostics become essential in such cases. Aging can lead to changes in
physiological functions, including a slower immune response and decreased organ
function. This can make sepsis more challenging to detect and manage in older
adults. Recognizing the vulnerability of the elderly population to sepsis,
healthcare providers and institutions often prioritize preventive measures,
including early diagnosis through diagnostic tests.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Sepsis Diagnostics Market”
Sepsis
is thus one of the major reasons of death in COVID-19 patients. Most diagnostic
tests available today can process and offer results in up to 72 hours. Because
early sepsis detection could save thousands of lives, there is a huge market
need for quick diagnostic tests. A novel and affordable test for an early
diagnosis of this illness was discovered in February 2019 by researchers at the
University of Strathclyde. The results of this recently created test, which
analyses the patients' blood using a microelectrode, can be obtained in about
two and a half minutes.
In
August 2022, Accelerate Diagnostics, Inc. a pioneer in rapid in-vitro
diagnostics in microbiology, and BD, a leading global medical technology
company, announced a worldwide commercial collaboration agreement. Under the
terms of the agreement, BD will offer Accelerate's rapid testing solution for
antibiotic resistance and susceptibility, which provides results in hours as
opposed to one to two days with some traditional laboratory methods. According
to the agreement, BD will use its global sales network to promote and sell the
Accelerate Pheno system, Accelerate ArcTM module, and related test kits in
regions where the products have received regulatory approval or registration.
These products enhance BD's current Clinical Microbiology offering and further
the firm’s joint objective of addressing the global problem posed by antibiotic
resistance.
Compliance and adherence
can pose challenges in the global sepsis diagnostics market, particularly in
healthcare settings where sepsis diagnosis and management protocols need to be
followed rigorously. Healthcare providers often follow clinical guidelines for
sepsis diagnosis and management. However, adherence to these guidelines can
vary among different healthcare facilities and providers. Ensuring consistent
adherence to best practices is a challenge. The timely diagnosis of sepsis is crucial for effective treatment.
Compliance with diagnostic protocols, including the prompt collection of blood
cultures and ordering appropriate tests, is essential. Delays or non-compliance
can lead to delayed diagnosis and treatment. Adherence to appropriate test utilization is vital to avoid unnecessary
testing and associated costs. Overuse or underuse of diagnostic tests can
impact patient care and healthcare resources. Accurate interpretation of diagnostic test results is critical.
Healthcare providers must be knowledgeable about the significance of various
biomarkers, blood culture results, and other diagnostic findings related to
sepsis.
Global Sepsis Diagnostics Market segmentation
is based on Technology, Product,
Diagnostics Method, Pathogen, and Region.
Based on Pathogen, Global
Sepsis Diagnostics Market is segmented into Bacterial Sepsis, Fungal Sepsis,
and Other Pathogens.
Fungal sepsis, also known as fungal bloodstream infection or fungemia, is a
severe medical condition that occurs when fungi enter the bloodstream and cause
a systemic infection. Fungi are microorganisms that can infect various parts of
the body, including the bloodstream, leading to a life-threatening condition.
Fungal sepsis is less common than bacterial sepsis but can be equally
dangerous. Various fungal species can cause fungemia. Candida species, such as
Candida albicans, are the most common culprits, but other fungi like
Aspergillus, Cryptococcus, and others can also lead to fungal sepsis. When
fungi invade the bloodstream, the body's immune system responds by initiating
an inflammatory reaction to combat the infection. While this response is
essential for defense, an overly aggressive or dysregulated immune response can
lead to systemic inflammation. Antifungal medications, such as fluconazole,
amphotericin B, or echinocandins, are used to target and eliminate the fungal
infection. The choice of antifungal therapy depends on the specific fungal
species and the patient's clinical condition.
Based on Region, North America dominated the Global
Sepsis Diagnostics Market.
North America, particularly the United States and Canada, boasts a highly developed
and advanced healthcare infrastructure. The presence of modern hospitals,
well-equipped laboratories, and state-of-the-art medical facilities allows for
the effective diagnosis and management of sepsis. The region has a relatively
high incidence of sepsis cases. Factors such as an aging population, the
prevalence of chronic diseases, and many surgical procedures contribute to a
substantial sepsis patient population. North America has stringent regulatory
standards for diagnostic tests and medical devices. The rigorous regulatory
environment encourages the development and adoption of accurate and reliable
sepsis diagnostic technologies. The region is home to numerous pharmaceutical
and diagnostic companies that invest heavily in research and development. This
has resulted in the development of innovative sepsis diagnostic products and
technologies.
Asia-pacific region to fastest growth in
the Global Sepsis Diagnostics Market. The Asia-Pacific region has a significant
disease burden, with a large population and a relatively higher prevalence of
infectious diseases. Factors such as densely populated urban areas and limited
access to healthcare in some regions can contribute to the spread of
infections, increasing the risk of sepsis. The region has some of the world's
most populous countries, including China and India. Rapid population growth has
led to increased healthcare needs, including the demand for sepsis diagnostics.
Many countries in the Asia-Pacific region have been increasing their healthcare
budgets and investing in healthcare infrastructure. This includes improvements
in laboratory facilities and the adoption of advanced diagnostic technologies.
Some of the major companies
operating in the Global Sepsis Diagnostics Market include:
- Abbott Laboratories Inc.
- DiaSorin SpA
- Becton, Dickinson, and Company
- BioMerieux Inc.
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- Seegene, Inc.
- Roche Diagnostics Corporation
Download Free Sample Report
Customers
can also request 10% free customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
for Sepsis diagnostics. The growth in the competitive landscape and the
presence of well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Sepsis Diagnostics Market in the forecast period,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Sepsis Diagnostics Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by
Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other
Technologies), By Product (Instruments, Assays and Reagents, and Other
Products), By Diagnostic Method (Conventional Diagnostics and Automated
Diagnostics), By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other
Pathogens), and By Region, Competition evaluated
the future growth potential of Global Sepsis Diagnostics Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Sepsis Diagnostics Market.
Contact
Techsci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com